Articles from ConcertAI

ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization, ​and interoperability solutions, today announced TeraRecon AV™*, an advanced medical imaging visualization solution that enhances clinician diagnostic precision, streamlines processes, and improves patient care with AI-driven automation and new specialized clinical tools. Its secure, cloud-based infrastructure integrates seamlessly with any existing Radiology or Cardiology Picture Archiving and Communication System (PACS) to create a standardized imaging enterprise that supports diverse needs across sub-specialties.

ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization, ​and interoperability solutions, today announced TeraRecon DETECTTM, an AI-powered platform that helps identify opportunities to optimize reimbursement for multiple imaging biomarkers. With TeraRecon DETECTTM, patients get improved screening with more confident diagnoses, clinicians spend more time with their patients than on paperwork, and administrators can streamline operational workflows to ultimately help optimize reimbursement potential.

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the appointment of Dr. Shaalan Beg as ConcertAI’s chief medical officer, oncology. In his new role, Dr. Beg will lead efforts to grow and engage the CancerLinQ community, ensuring the voices of practicing oncologists and their evolving patient needs are translated into actionable product development insights and innovations across the broader ConcertAI portfolio.

ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization ​and interoperability solutions, today announced it has surpassed 2,000 global customers. This milestone reflects the continued acceleration of the company’s cloud-first SaaS transformation with an enterprise-level solution used across clinical imaging domains such as vascular surgery, interventional radiology and cardiology, as well as its success of targeted international expansion strategies designed to meet the complex requirements of diverse healthcare markets.

ConcertAI, a leading provider of multi-modal data and agentic AI solutions for life sciences and healthcare, today announced the appointment of Casey Graves as general manager of Clinical Solutions. In this pivotal role, Graves will drive growth and innovation in real-world data (RWD) and AI solutions for oncology research and clinical care, accelerating advances that improve outcomes for patients and healthcare providers.

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced its initiative, CancerLinQ®, is now a recognized quality solution for clinical quality measures data for ASCO Certified. As an ASCO Recognized Quality Solution (RQS) provider, CancerLinQ automates quality tracking for ASCO Certified practices, saving clinical teams an average of 4-20 hours a week (depending on the practice size) from manual abstraction, redirecting time for patient care. ASCO RQS enables CancerLinQ’s oncology practices to more easily submit quality measure data for ASCO Certified—creating a frictionless experience for health system and oncology practice partners. Achieving this recognition demonstrates CancerLinQ's dedication to data integrity, supporting oncology practice partners and improving patient care.

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the appointment of Michael Myshrall as chief financial officer (CFO). Myshrall brings over two decades of financial leadership experience in SaaS, artificial intelligence (AI) and technology sectors, positioning him to help accelerate ConcertAI's continued expansion and innovation in AI-powered clinical research and care.

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite’s low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes.

ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value.

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data solutions for healthcare and life sciences, announced today that Eron Kelly has been appointed Chief Executive Officer. Kelly succeeds Dr. Jeff Elton, who will transition from his role as CEO to Vice Chairman of the company.

ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ -- powered by Guardant Health liquid biopsy genomic data -- and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.

ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.

Ernst & Young LLP (EY US) has announced the finalists for the prestigious Entrepreneur Of The Year 2025 New England Award. Now in its 40th year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world’s most ground-breaking companies, revolutionizing industries and making a profound impact on communities. The program honors bold entrepreneurs whose innovations shape the future and pave the way for a thriving economy and a hopeful tomorrow.

ConcertAI's TeraRecon, a leader in integrating advanced imaging workflows with clinical AI, has announced an expanded partnership with 3DR® Labs, a leading provider of 3D medical image post-processing and clinically integrated AI services in the United States. This collaboration aims to enhance clinical service delivery for advanced imaging by expanding the range of domain-specific workflows and clinical AI technologies. As a result, it will benefit numerous hospitals across the country.

Exigent Research and ConcertAI announced a major multi-year partnership to assure potentially lifesaving clinical trials are available to the broadest population of patients possible, combining the growing Exigent community oncology research network with a full suite of ConcertAI technologies providing study feasibility, patient-to-trial matching, and AI-powered study automations.

ConcertAI, a leader in oncology predictive and generative AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences is presenting and exhibiting at NVIDIA GTC25 in San Jose, CA. ConcertAI will showcase the latest advances in the CARAai™ platform with a multi-agentic AI development and deployment framework, proprietary multi-small language model (SLM), and multi-large language models (LLMs) tuned for different aspects of oncology insights and clinical development. Many of the AI SaaS solutions being presented and demonstrated at GTC25 are part of the ConcertAI collaboration with NVIDIA announced in June 2024.

ConcertAI, a leader in oncology predictive, generative, and agentic AI SaaS and Real-World Data (RWD) solutions for healthcare and life sciences, today outlined its FY2024 business results, key partnerships, and future roadmap at the 43rd annual J.P. Morgan Healthcare Conference.

At the opening of SCOPE 2025, ConcertAI and Exigent Research announced the availability of ConcertAI technologies for study feasibility, patient-to-trial matching, and AI-powered study automations across all Exigent research sites and as an integral part of all sponsored studies. The partnership ensures that advanced CARAai™ Generative and Agentic AI solutions are available to provide the highest possible performance and lowest burden for the network’s leading community research sites. A few weeks earlier, NeoGenomics and ConcertAI announced the collaborative launch of an AI Software-as-a-Service solution for hematological malignancies, guiding protocol optimization and study design for all major hematological diseases with exceptional biomarker depth and data longitudinality.

ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collaboration jointly announced on Jan. 8, 2024, and the more recent joint research completed and scheduled for presentation at the 2024 American Society of Hematology Meeting on Monday, Dec. 9, in San Diego.

ConcertAI, the leader in predictive and generative AI SaaS and DaaS solutions for healthcare and life sciences, today announced a Software-as-a-Service (SaaS) cloud version of TeraRecon’s AI-enabled portfolio of advanced visualization (AV) and generative AI modules for clinical workflows. This is a milestone in making the best-in-class solution more accessible to healthcare providers, and brings together Intuition Advanced Visualization, Eureka Clinical AI, and CARAai™ in one cloud platform. This addition of the SaaS platform allows healthcare organizations to utilize the latest TeraRecon solutions in different configurations at the enterprise and network levels and assures consistency in AI enabled-workflows everywhere.

TeraRecon, the leader in medical imaging advanced visualization, clinical AI, and workflow automation, today announced updates to its Intuition platform with new best-in-class cardiac magnetic resonance (MR) medical imaging capabilities. These clinical innovations are now available across all deployment models and on the latest cloud infrastructure.

ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that James Salitan has joined the company as General Counsel.